Last updated: February 5, 2026
RYTARY Manufacturer and Primary Supplier
RYTARY (carbidopa-levodopa) Extended-Release Capsules is produced by Neurocrine Biosciences. The drug combines carbidopa and levodopa in a sustained-release formulation used primarily to treat Parkinson’s disease.
Manufacturers and Key Raw Material Suppliers
Neurocrine Biosciences is responsible for RYTARY's manufacturing process, including formulation development and quality control. The active pharmaceutical ingredients (APIs)—carbidopa and levodopa—are procured from multiple global suppliers.
Active Pharmaceutical Ingredients (APIs)
-
Levobupivacaine: Sourced from suppliers with Good Manufacturing Practice (GMP) certification, primarily in India, China, and Europe.
-
Carbidopa: Major suppliers include Novartis (raw material manufacturing licensing) and generic API producers based in India and China.
Key Suppliers for APIs
| Supplier Location |
API |
Market Share |
Notes |
| India |
Carbidopa |
60%+ |
Major exporter; many certified API producers including SeQuent Medical, Hetero, and Cipla. |
| China |
Levodopa |
70%+ |
Number of suppliers; variable quality control. |
| Europe |
Carbidopa |
25% |
European API manufacturers like Fareva supply high-grade APIs. |
Excipients and Formulation Materials
Excipients used in RYTARY include fillers, binders, and coating agents sourced globally, chiefly from North America, Europe, and Asia. Suppliers include:
- Colorants and stabilizers: Major chemical companies such as BASF, Clariant, and Dainippon Sumitomo.
Manufacturing Facilities
- Neurocrine Biosciences owns but outsources actual drug production to cGMP-compliant third-party facilities in North America and Europe. This multi-sourcing reduces dependency risks but introduces logistical complexities.
Distribution Network and Logistics
- RYTARY distribution relies on global pharmaceutical logistics networks, primarily in North America, Europe, and parts of Asia. This network spreads suppliers' risk but is sensitive to geopolitical and supply chain disruptions.
Supply Chain Risks
- Dependence on APIs from China and India exposes RYTARY supply to geopolitical risks, export restrictions, and quality control challenges.
- Short-term shortages have occurred due to manufacturing delays at API suppliers and COVID-19 related disruptions.
- Regulatory shifts, such as increased API quality standards, could impact supplier eligibility.
Strategic Supply Chain Developments
- Neurocrine Biosciences has pursued dual sourcing for APIs in recent years to mitigate supply risks.
- The company expanded collaborations with European API manufacturers to reduce dependence on Asian sources.
- API suppliers must comply with U.S. FDA, EMA, and other regulatory standards, which can impact supplier selection and product approval.
Regulatory Compliance
- Suppliers must adhere to cGMP standards, with periodic audits by Neurocrine and regulatory agencies.
- Suppliers exporting to the U.S. and Europe require certifications such as USFDA (FDA Warning Letters can impact supply) and EMA approvals.
Key Takeaways
- Neurocrine Biosciences manages RYTARY’s manufacturing, sourcing APIs primarily from India, China, and Europe.
- API dependence on Asian suppliers presents geopolitical and quality risks.
- The company diversifies suppliers and expands European partnerships to manage supply chain stability.
- Regulatory compliance is critical for supplier selection and ongoing quality assurance.
- Disruptions in raw material supply can lead to shortages, impacting market availability.
Frequently Asked Questions
1. Who manufactures the APIs used in RYTARY?
Major suppliers include Indian companies like SeQuent Medical, Hetero, Cipla, and Chinese manufacturers of levodopa. European suppliers such as Fareva also produce high-quality carbidopa.
2. How does Neurocrine Biosciences ensure supply chain stability?
The company employs dual sourcing strategies, partnerships with European API producers, and strict supplier audits to mitigate disruptions.
3. What are the main risks affecting RYTARY's supply?
API shortages due to geopolitical trade restrictions, manufacturing delays, and quality compliance issues pose the greatest risks.
4. Are there seasonal or geopolitical factors affecting supply?
Yes. Trade tensions between China and the U.S., COVID-19 disruptions, and regional manufacturing capacity constraints impact supply.
5. Can the dependency on Asian API suppliers impact RYTARY's market availability?
Yes, geopolitical and regulatory shifts could result in supply constraints or increased costs, affecting distribution and pricing.
Citations
- Neurocrine Biosciences. RYTARY product information.
- IQVIA. Global API market data.
- U.S. FDA database. API manufacturing facility inspections.
- Global trade data for pharmaceutical ingredients.
- Industry reports on pharmaceutical supply chain risks.
